Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02923011 · ClinicalTrials.gov registry record · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
A Phase 3 study of Osteoid Osteoma, sponsored by Matthew Bucknor.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 56
- Enrollment target
- 3
- Study locations
NCT02923011 is a Phase 3 study of Osteoid Osteoma that is actively recruiting participants, run by Matthew Bucknor. The registered enrollment target is 56 participants. The trial reports 3 study locations across 2 states.
The verdict
NCT02923011, a Phase 3 study of Osteoid Osteoma, is actively recruiting participants, sponsored by Matthew Bucknor.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 56 participants
- Enrollment target
- 3
- Study locations
Study Summary
Osteoid osteomas are painful, benign bone tumors that occur most frequently in young males between ages 10 and 20 years. The goal of the proposed study is based on the premise that MRgFUS is noninferior to CT-guided radiofrequency ablation (CTgRFA), in terms of pain reduction following treatment of osteoid osteomas, and offers possible improvements with regards to 1) post-procedural pain, 2) clinical resource utilization, 3) patient experience, and/or 4) adverse events. The data from the current study would provide clinicians important information in deciding between treatment options for ablation of osteoid osteomas.
Conditions Studied
Interventions
- DEVICE MRgFUS
- DEVICE CTgRFA
Study Locations (3)
California
- Stanford Medical Center - Palo Alto
- UCSF Imaging Center - San Francisco
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2017-03-28 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02923011
The ClinicalTrials.gov registry entry for NCT02923011 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Matthew Bucknor, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteoid Osteoma appearing as the primary indexed condition, and to 2 interventions - of which MRgFUS is the first listed.
NCT02923011 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02923011 about?
NCT02923011 is a clinical study titled "Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas". Osteoid osteomas are painful, benign bone tumors that occur most frequently in young males between ages 10 and 20 years. The goal of the proposed study is based on the premise that MRgFUS is noninferior to CT-guided radiofrequency ablation (CTgRFA), in terms of pain reduction following treatment of ...
What is the current status of trial NCT02923011?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 56 participants. The study started on 2017-03-28. Estimated completion is 2025-06-30.
What conditions does trial NCT02923011 study?
This clinical trial studies the following conditions: Osteoid Osteoma.
What interventions are being tested in trial NCT02923011?
The interventions under investigation include: MRgFUS (DEVICE), CTgRFA (DEVICE).
Who is sponsoring clinical trial NCT02923011?
This trial is sponsored by Matthew Bucknor, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02923011 being conducted?
This trial has 3 study locations across California, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoid Osteoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.